Marisa Wexler, MS, Author at MYELOMA360

1st 4 patients in AML treatment combo trial show response

by Marisa Wexler, MS | Jan 12, 2026 | Myeloma News

All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and AB Science‘s experimental therapy AB8939 have responded to treatment, according to an update from AB. The company previously...

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

by MM360 Staff | Jan 10, 2026 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis

by MM360 Staff | Jan 10, 2026 | Publications

Hematology. 2026 Dec;31(1):2613505. doi: 10.1080/16078454.2026.2613505. Epub 2026 Jan 8. ABSTRACT Objectives: The introduction of novel therapies has markedly improved the prognosis of multiple myeloma (MM), yet relapse remains common. For patients with relapsed or...

by MM360 Staff | Jan 10, 2026 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

by MM360 Staff | Jan 10, 2026 | Uncategorized

Source: CURE articles Post Content Read More

1st 4 patients in AML treatment combo trial show response

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis

Recent Content